Loading content
Dr Angus Jones

Dr Angus Jones

NIHR Clinician Scientist/Honorary Consultant Physician

01392 408538

RILD Building 

Angus is a Clinical Senior Lecturer at the University of Exeter and an Honorary Consultant (Diabetes and Acute Medicine) in the Royal Devon and Exeter Hospital. He trained in medicine in London and worked as a clinician in London, Southampton, Malawi and Southwest England before undertaking an NIHR Doctoral Research Fellowship with Professor Andrew Hattersley in Exeter from 2011 to 2014. His research focuses on clinical questions directly relevant to the management of diabetes. Interests include developing a stratified (or personalised) approach to the management of Type 2 diabetes, diabetes classification and the assessment of endogenous insulin secretion (C-peptide) in the clinical management of diabetes.  He received an NIHR Clinician Scientist Fellowship in 2016 to investigate and integrate biomarkers and clinical features for diabetes classification in adults, research that is using a combination of existing datasets, electronic healthcare records and prospective studies to develop a fully validated prediction model (clinical calculator) for diabetes classification at diagnosis. He was awarded the Diabetes UK Type 2 Diabetes Research Prize in both 2014 and 2015 and a European Foundation for the Study of Diabetes Rising Star Award in 2016. 

Qualifications

  • 2000 BSc. Clinical and Biological Sciences (1st), University of London (Imperial) 
  • 2001 MBBS, University of London (St. Georges)
  • 2004 MRCP (UK)
  • 2005 DTM&H, University of Liverpool
  • 2008 Pg Cert Ed, Peninsula College of Medicine and Dentistry, Universities of Exeter and Plymouth
  • 2014 PhD, Peninsula College of Medicine and Dentistry, Universities of Exeter and Plymouth
  • 2016 CCT Endocrinology & General (Internal) Medicine

Research

Research projects

  • StartRight (NIHR Clinican Scientist Award) - Getting the right classification and treatment from diagnosis in young adults with diabetes
  • PRIBA (NIHR Doctoral Research Fellowship) - Identifying clinical and biomarker predictors of response to incretin based therapies for type 2 diabetes
  • Using a genetic risk score to identify patients with type 1 diabetes who will require early insulin therapy (EFSD Rising Star Fellowship)
  • MASTERMIND (MRC) - Stratification of treatment response in type 2 diabetes
  • GREAT (NIHR Exeter Clinical Research Facility/Northcott Devon Foundation) - C-peptide and hypoglcyaemia risk in Type 2 diabetes
  • DIRECT (EU IMI) - Stratification of Type 2 diabetes
  • DIVA (MRC) Defining the molecular and physiological mechanisms of pancreatic islet dysfunction which lead to type 2 diabetes

 

Key publications | Publications by category | Publications by year

Publications by category


Journal articles

Hope S, Wienand-Barnett S, Shepherd M, King S, Fox C, Khunti K, Oram R, Knight B, Hattersley A, Jones A, et al (In Press). Assessment of Practical Classification Guidelines for Diabetes in insulin-treated patients. British Journal of General Practice Full text.
Chakera AJ, McDonald TJ, Knight BA, Vaidya B, Jones AG (2017). Current laboratory requirements for adrenocorticotropic hormone and renin/aldosterone sample handling are unnecessarily restrictive. Clin Med (Lond), 17(1), 18-21. Abstract.  Author URL.  Full text.
Preiss D, Dawed A, Welsh P, Heggie A, Jones AG, Dekker J, Koivula R, Hansen TH, Stewart C, Holman RR, et al (2017). Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. Diabetes Obes Metab, 19(3), 356-363. Abstract.  Author URL.
Oram RA, Patel K, Hill A, Shields B, McDonald TJ, Jones A, Hattersley AT, Weedon MN (2016). A Type 1 Diabetes Genetic Risk Score can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. Diabetes Care, 39(3), 337-344. Abstract.  Author URL.  Full text.
Jones AG, McDonald TJ, Shields BM, Hill AV, Hyde CJ, Knight BA, Hattersley AT, PRIBA Study Group (2016). Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care, 39(2), 250-257. Abstract.  Author URL.  Full text.
Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG (2016). Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabet Med, 33(11), 1554-1558. Abstract.  Author URL.  Full text.
Jones AG, Lonergan M, Henley WE, Pearson ER, Hattersley AT, Shields BM (2016). Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?. PLoS One, 11(4). Abstract.  Author URL.  Full text.
Shields BM, Peters JL, Cooper C, Lowe J, Knight BA, Powell RJ, Jones A, Hyde CJ, Hattersley AT (2015). Can clinical features be used to differentiate type 1 from type 2 diabetes? a systematic review of the literature. BMJ Open, 5(11). Abstract.  Author URL.  Full text.
Jones AG, McDonald TJ, Hattersley AT, Shields BM (2014). Effect of the holiday season in patients with diabetes: Glycemia and lipids increase postholiday, but the effect is small and transient. Diabetes Care, 37(5).
Oram RA, Jones AG, Besser RE, Knight BA, Shields BM, Brown RJ, Hattersley AT, McDonald TJ (2014). Erratum to: the majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 57(1). Author URL.
Jones AG, Shields BM, Hyde CJ, Henley WE, Hattersley AT (2014). Identifying good responders to glucose lowering therapy in type 2 diabetes: implications for stratified medicine. PLoS One, 9(10). Abstract.  Author URL.  Full text.
Oram RA, Jones AG, Besser REJ, Knight BA, Shields BM, Brown RJ, Hattersley AT, McDonald TJ (2014). The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 57(1), 187-191. Abstract.
Jones AG, Hill AV, Stewart J, Githens-Mazer G, Shields BM, McDonald TJ, Knight BA, Hattersley AT (2013). Baseline HbA1c is the major clinical predictor of glycaemic response to incretin based agents in Type 2 diabetes. DIABETIC MEDICINE, 30, 164-164. Author URL.
Jones AG, Knight BA, Baker GC, Hattersley AT (2013). Practical implications of choice of test in National Institute for Health and Clinical Excellence (NICE) guidance for the prevention of Type 2 diabetes. Diabet Med, 30(1), 126-127. Author URL.
Jones AG, Hattersley AT (2013). The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine, 30(7), 803-817. Abstract.  Full text.
Hope SV, Jones AG, Goodchild E, Shepherd M, Besser REJ, Shields B, Mcdonald T, Knight BA, Hattersley A (2013). Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabetic Medicine, 30(11), 1342-1348. Abstract.
Hope SV, Jones AG, Goodchild E, Shepherd M, Besser REJ, Shields B, McDonald T, Knight BA, Hattersley A (2013). Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabet Med, 30(11), 1342-1348. Abstract.  Author URL.  Full text.
Jones AG, Besser REJ, Shields BM, McDonald TJ, Hope SV, Knight BA, Hattersley AT (2012). Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin. BMC Endocrine Disorders, 12 Abstract.  Full text.
Jones AG, Evans PH, Vaidya B (2012). Phaeochromocytoma. BMJ, 344 Author URL.
Thomas NJ, Shields BM, Besser REJ, Jones AG, Rawlingson A, Goodchild E, Leighton C, Bowman P, Shepherd M, Knight BA, et al (2012). The impact of gender on urine C-peptide creatinine ratio interpretation. Ann Clin Biochem, 49(Pt 4), 363-368. Abstract.  Author URL.
Besser REJ, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2012). The impact of insulin administration during the mixed meal tolerance test. Diabet Med, 29(10), 1279-1284. Abstract.  Author URL.
McDonald TJ, Perry MH, Jones AG, Donohoe M, Salzmann MB, O'Connor J (2011). A novel case of a raised testosterone and LH in a young man. Clinica Chimica Acta, 412(21-22), 1999-2001. Abstract.
Jones A, Bull M, Vaidya B (2011). A woman with episodic headaches, sweating, and palpitations. BMJ, 342 Author URL.
Jones A, Bull M, Vaidya B (2011). PICTURE QUIZ a woman with episodic headaches, sweating, and palpitations. BRITISH MEDICAL JOURNAL, 342 Author URL.
Besser REJ, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2011). Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care, 34(3), 607-609. Abstract.  Author URL.
Jones AG, Besser REJ, McDonald TJ, Shields BM, Hope SV, Bowman P, Oram RA, Knight BA, Hattersley AT (2011). Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes. Diabet Med, 28(9), 1034-1038. Abstract.  Author URL.
Jones AG, Hattersley AT (2010). Reevaluation of a case of type 1 diabetes mellitus diagnosed before 6 months of age. Nat Rev Endocrinol, 6(6), 347-351. Abstract.  Author URL.
Edwards RJ, Taylor GW, Ferguson M, Murray S, Rendell N, Wrigley A, Bai Z, Boyle J, Finney SJ, Jones A, et al (2005). Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J Infect Dis, 192(5), 783-790. Abstract.  Author URL.

Chapters

Jones AG, Vaidya B (2014). Preoperative endocrine function and fluid electrolyte balance. In  (Ed) Pituitary Apoplexy, 95-105.  Abstract.
Jones AG, Hattersley AT (2011). Monogenic causes of diabetes. In Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ (Eds.) Textbook of Diabetes, John Wiley & Sons.

Conferences

Grubb AL, Patel KA, Oram RA, Hill AV, Angwin C, McDonald TJ, Weedon MN, Hattersley AT, Shields BV, Jones AG, et al (2017). Development of a risk calculator to identify patients with Type 1 diabetes who will require early insulin therapy.  Author URL.
Patel KA, Hill A, Shields BM, Oram RA, Jones A, Hattersley AT (2017). Type 2 diabetes and severe insulin deficiency.  Author URL.
Dawed AY, Jones AG, McDonald TJ, Walker M, Mari A, Franks PW, Pearson ER, Project IMI-DIRECT (2016). Determinants of glucagon secretion in prediabetes and recently diagnosed type 2 diabetes: an IMI-DIRECT study.  Author URL.
Hope SV, Knight BA, Shields BM, Strain WD, Hattersley AT, Choudhary P, Jones AG (2016). Low c-peptide is associated with high glycaemic variability and hypoglycaemia in insulin-treated patients with Type 2 diabetes.  Author URL.
Shields BM, Dennis JM, Henley W, Weedon M, Lonergan M, Rodgers L, Jones AG, Holman RR, Pearson ER, Hattersley AT, et al (2016). Personalising therapy in type 2 diabetes: the effect of BMI and sex on glycaemic response and side effects to sulphonylureas and thiazolidinediones.  Author URL.
Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG (2016). Random non-fasting c-peptide provides an accurate measure of endogenous insulin secretion for clinical practice.  Author URL.
Dennis JM, Hattersley AT, Henley WE, Jones AG, Pearson ER, Shields BM (2016). Stratification using gender and body mass index (BMI) can predict side-effect risk in people with Type 2 diabetes initiating thiazolidinediones but not sulphonylureas: a MASTERMIND study.  Author URL.  Full text.
Craig ZV, Hill AV, McDonald TJ, Hattersley AT, Jones AG, Shields BM (2016). Time to change the HbA1c cut-off for prediabetes.  Author URL.
Weedon MN, Hill AV, McDonald TJ, Patel KA, Jones A, Hattersley AT, Oram R (2015). A novel inexpensive test can discriminate between Type 1 and Type 2 diabetes.  Author URL.
Jones AG, Lonergan M, Rodgers LR, Henley WE, Pearson EW, Hattersley AT, Shields BM, Consortium M (2015). Studies of diabetes treatment stratification should correct for baseline HbA1c: a MASTERMIND study.  Author URL.
Jones AG, McDonald TJ, Hill AV, Stewart J, Shields BM, Knight BA, Hattersley AT (2014). Markers of beta cell failure are associated with reduced glycaemic response to GLP-1 agonists in Type 2 diabetes.  Author URL.
Knight BA, Shields BM, Baker GC, Hattersley AT, Jones AG (2013). Effectiveness of screening questionnaires to detect HbA1c defined abnormal glycaemia in a UK White population.  Author URL.
Jones AG, Hill AV, Stewart J, Shields BM, McDonald TJ, Knight BA, Hattersley AT (2013). Markers of insulin resistance and beta cell function do not predict response to incretin based treatments in type 2 diabetes.  Author URL.
Oram RA, McDonald TJ, Jones AG, Besser REJ, Hattersley AT (2013). The majority of patients with over five years of Type 1 diabetes are insulin microsecretors and have functioning beta cells.  Author URL.
Hope SV, Jones AG, Shepherd M, Shields B, Strain D, McDonald T, Knight BA, Hattersley AT (2013). Urinary C-peptide creatinine ratio to detect absolute insulin deficiency in type 2 diabetes.  Author URL.
Knight BA, Shields B, Baker G, Hattersley A, Jones A (2012). Screening questionnaires are useful in identifying undiagnosed HbA(1c) diagnosed diabetes in a Caucasian population.  Author URL.
Thomas NJM, Besser REJ, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2011). Simple and convenient alternatives to the mixed meal tolerance test.  Author URL.
Hope SV, Jones A, Goodchild E, Shepherd M, Besser REJ, Shields B, McDonald T, Knight BA, Hattersley A (2011). URINARY C-PEPTIDE CREATININE RATIO (UCPCR) CAN BE USED AS a SCREENING TOOL TO DETECT ABSOLUTE INSULIN DEFICIENCY IN PEOPLE WITH TYPE 2 DIABETES.  Author URL.
Shields BM, Shepherd MH, McDonald T, Besser REJ, Jones AG, Raju NB, Wensley KJ, Githens-Mazer G, Knight BA, Hattersley AT, et al (2010). Clinical Criteria Are Poor at Identifying Type 1 Diabetes. Should We be Measuring Insulin Deficiency Directly?.  Author URL.
Jones AG, Hope SV, Shepherd M, Shields BM, Besser REJ, Wensley KJ, Githens-Mazer G, McDonald TJ, Knight BA, Hattersley AT, et al (2010). Do patients with Long-Standing Type 2 Diabetes Develop Absolute Insulin Deficiency?.  Author URL.
Jones AG, Besser REJ, McDonald TJ, Wensley KJ, Githens-Mazer G, Shields BM, Knight BA, Hattersley AT (2010). Serum Measurement of Endogenous C-Peptide after a Mixed Meal can be Replaced with a Single Post Meal Urine C-Peptide Creatinine Ratio (UCPCR).  Author URL.
Shields BM, McDonald TJ, Bowman P, Jones AG, Besser REJ, Wensley KJ, Githens-Mazer G, Knight BA, Hattersley AT (2010). Urinary C-Peptide Creatinine Ratio (UCPCR) is a Reliable Measure of Endogenous Insulin Secretion, Even in Patients with Renal Impairment.  Author URL.
Besser REJ, Jones AG, McDonald TJ, Shields BM, Githens-Mazer G, Wensley K, Knight BA, Hattersley AT (2010). Urinary C-Peptide Creatinine Ratio is a Novel Non Invasive Alternative to the Inpatient Mixed Meal Tolerance Test in Young Onset Type 1 Diabetes.  Author URL.

Publications by year


In Press

Hope S, Wienand-Barnett S, Shepherd M, King S, Fox C, Khunti K, Oram R, Knight B, Hattersley A, Jones A, et al (In Press). Assessment of Practical Classification Guidelines for Diabetes in insulin-treated patients. British Journal of General Practice Full text.

2017

Chakera AJ, McDonald TJ, Knight BA, Vaidya B, Jones AG (2017). Current laboratory requirements for adrenocorticotropic hormone and renin/aldosterone sample handling are unnecessarily restrictive. Clin Med (Lond), 17(1), 18-21. Abstract.  Author URL.  Full text.
Grubb AL, Patel KA, Oram RA, Hill AV, Angwin C, McDonald TJ, Weedon MN, Hattersley AT, Shields BV, Jones AG, et al (2017). Development of a risk calculator to identify patients with Type 1 diabetes who will require early insulin therapy.  Author URL.
Preiss D, Dawed A, Welsh P, Heggie A, Jones AG, Dekker J, Koivula R, Hansen TH, Stewart C, Holman RR, et al (2017). Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. Diabetes Obes Metab, 19(3), 356-363. Abstract.  Author URL.
Patel KA, Hill A, Shields BM, Oram RA, Jones A, Hattersley AT (2017). Type 2 diabetes and severe insulin deficiency.  Author URL.

2016

Oram RA, Patel K, Hill A, Shields B, McDonald TJ, Jones A, Hattersley AT, Weedon MN (2016). A Type 1 Diabetes Genetic Risk Score can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. Diabetes Care, 39(3), 337-344. Abstract.  Author URL.  Full text.
Dawed AY, Jones AG, McDonald TJ, Walker M, Mari A, Franks PW, Pearson ER, Project IMI-DIRECT (2016). Determinants of glucagon secretion in prediabetes and recently diagnosed type 2 diabetes: an IMI-DIRECT study.  Author URL.
Hope SV, Knight BA, Shields BM, Strain WD, Hattersley AT, Choudhary P, Jones AG (2016). Low c-peptide is associated with high glycaemic variability and hypoglycaemia in insulin-treated patients with Type 2 diabetes.  Author URL.
Jones AG, McDonald TJ, Shields BM, Hill AV, Hyde CJ, Knight BA, Hattersley AT, PRIBA Study Group (2016). Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care, 39(2), 250-257. Abstract.  Author URL.  Full text.
Shields BM, Dennis JM, Henley W, Weedon M, Lonergan M, Rodgers L, Jones AG, Holman RR, Pearson ER, Hattersley AT, et al (2016). Personalising therapy in type 2 diabetes: the effect of BMI and sex on glycaemic response and side effects to sulphonylureas and thiazolidinediones.  Author URL.
Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG (2016). Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabet Med, 33(11), 1554-1558. Abstract.  Author URL.  Full text.
Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG (2016). Random non-fasting c-peptide provides an accurate measure of endogenous insulin secretion for clinical practice.  Author URL.
Jones AG, Lonergan M, Henley WE, Pearson ER, Hattersley AT, Shields BM (2016). Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?. PLoS One, 11(4). Abstract.  Author URL.  Full text.
Dennis JM, Hattersley AT, Henley WE, Jones AG, Pearson ER, Shields BM (2016). Stratification using gender and body mass index (BMI) can predict side-effect risk in people with Type 2 diabetes initiating thiazolidinediones but not sulphonylureas: a MASTERMIND study.  Author URL.  Full text.
Craig ZV, Hill AV, McDonald TJ, Hattersley AT, Jones AG, Shields BM (2016). Time to change the HbA1c cut-off for prediabetes.  Author URL.

2015

Weedon MN, Hill AV, McDonald TJ, Patel KA, Jones A, Hattersley AT, Oram R (2015). A novel inexpensive test can discriminate between Type 1 and Type 2 diabetes.  Author URL.
Shields BM, Peters JL, Cooper C, Lowe J, Knight BA, Powell RJ, Jones A, Hyde CJ, Hattersley AT (2015). Can clinical features be used to differentiate type 1 from type 2 diabetes? a systematic review of the literature. BMJ Open, 5(11). Abstract.  Author URL.  Full text.
Jones AG, Lonergan M, Rodgers LR, Henley WE, Pearson EW, Hattersley AT, Shields BM, Consortium M (2015). Studies of diabetes treatment stratification should correct for baseline HbA1c: a MASTERMIND study.  Author URL.

2014

Jones AG, McDonald TJ, Hattersley AT, Shields BM (2014). Effect of the holiday season in patients with diabetes: Glycemia and lipids increase postholiday, but the effect is small and transient. Diabetes Care, 37(5).
Oram RA, Jones AG, Besser RE, Knight BA, Shields BM, Brown RJ, Hattersley AT, McDonald TJ (2014). Erratum to: the majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 57(1). Author URL.
Jones AG, Shields BM, Hyde CJ, Henley WE, Hattersley AT (2014). Identifying good responders to glucose lowering therapy in type 2 diabetes: implications for stratified medicine. PLoS One, 9(10). Abstract.  Author URL.  Full text.
Jones AG, McDonald TJ, Hill AV, Stewart J, Shields BM, Knight BA, Hattersley AT (2014). Markers of beta cell failure are associated with reduced glycaemic response to GLP-1 agonists in Type 2 diabetes.  Author URL.
Jones AG, Vaidya B (2014). Preoperative endocrine function and fluid electrolyte balance. In  (Ed) Pituitary Apoplexy, 95-105.  Abstract.
Oram RA, Jones AG, Besser REJ, Knight BA, Shields BM, Brown RJ, Hattersley AT, McDonald TJ (2014). The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 57(1), 187-191. Abstract.

2013

Jones AG, Hill AV, Stewart J, Githens-Mazer G, Shields BM, McDonald TJ, Knight BA, Hattersley AT (2013). Baseline HbA1c is the major clinical predictor of glycaemic response to incretin based agents in Type 2 diabetes. DIABETIC MEDICINE, 30, 164-164. Author URL.
Knight BA, Shields BM, Baker GC, Hattersley AT, Jones AG (2013). Effectiveness of screening questionnaires to detect HbA1c defined abnormal glycaemia in a UK White population.  Author URL.
Jones AG, Hill AV, Stewart J, Shields BM, McDonald TJ, Knight BA, Hattersley AT (2013). Markers of insulin resistance and beta cell function do not predict response to incretin based treatments in type 2 diabetes.  Author URL.
Jones AG, Knight BA, Baker GC, Hattersley AT (2013). Practical implications of choice of test in National Institute for Health and Clinical Excellence (NICE) guidance for the prevention of Type 2 diabetes. Diabet Med, 30(1), 126-127. Author URL.
Jones AG, Hattersley AT (2013). The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine, 30(7), 803-817. Abstract.  Full text.
Oram RA, McDonald TJ, Jones AG, Besser REJ, Hattersley AT (2013). The majority of patients with over five years of Type 1 diabetes are insulin microsecretors and have functioning beta cells.  Author URL.
Hope SV, Jones AG, Goodchild E, Shepherd M, Besser REJ, Shields B, Mcdonald T, Knight BA, Hattersley A (2013). Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabetic Medicine, 30(11), 1342-1348. Abstract.
Hope SV, Jones AG, Goodchild E, Shepherd M, Besser REJ, Shields B, McDonald T, Knight BA, Hattersley A (2013). Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabet Med, 30(11), 1342-1348. Abstract.  Author URL.  Full text.
Hope SV, Jones AG, Shepherd M, Shields B, Strain D, McDonald T, Knight BA, Hattersley AT (2013). Urinary C-peptide creatinine ratio to detect absolute insulin deficiency in type 2 diabetes.  Author URL.

2012

Jones AG, Besser REJ, Shields BM, McDonald TJ, Hope SV, Knight BA, Hattersley AT (2012). Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin. BMC Endocrine Disorders, 12 Abstract.  Full text.
Jones AG, Evans PH, Vaidya B (2012). Phaeochromocytoma. BMJ, 344 Author URL.
Knight BA, Shields B, Baker G, Hattersley A, Jones A (2012). Screening questionnaires are useful in identifying undiagnosed HbA(1c) diagnosed diabetes in a Caucasian population.  Author URL.
Thomas NJ, Shields BM, Besser REJ, Jones AG, Rawlingson A, Goodchild E, Leighton C, Bowman P, Shepherd M, Knight BA, et al (2012). The impact of gender on urine C-peptide creatinine ratio interpretation. Ann Clin Biochem, 49(Pt 4), 363-368. Abstract.  Author URL.
Besser REJ, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2012). The impact of insulin administration during the mixed meal tolerance test. Diabet Med, 29(10), 1279-1284. Abstract.  Author URL.

2011

McDonald TJ, Perry MH, Jones AG, Donohoe M, Salzmann MB, O'Connor J (2011). A novel case of a raised testosterone and LH in a young man. Clinica Chimica Acta, 412(21-22), 1999-2001. Abstract.
Jones A, Bull M, Vaidya B (2011). A woman with episodic headaches, sweating, and palpitations. BMJ, 342 Author URL.
Jones AG, Hattersley AT (2011). Monogenic causes of diabetes. In Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ (Eds.) Textbook of Diabetes, John Wiley & Sons.
Jones A, Bull M, Vaidya B (2011). PICTURE QUIZ a woman with episodic headaches, sweating, and palpitations. BRITISH MEDICAL JOURNAL, 342 Author URL.
Thomas NJM, Besser REJ, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2011). Simple and convenient alternatives to the mixed meal tolerance test.  Author URL.
Hope SV, Jones A, Goodchild E, Shepherd M, Besser REJ, Shields B, McDonald T, Knight BA, Hattersley A (2011). URINARY C-PEPTIDE CREATININE RATIO (UCPCR) CAN BE USED AS a SCREENING TOOL TO DETECT ABSOLUTE INSULIN DEFICIENCY IN PEOPLE WITH TYPE 2 DIABETES.  Author URL.
Besser REJ, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2011). Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care, 34(3), 607-609. Abstract.  Author URL.
Jones AG, Besser REJ, McDonald TJ, Shields BM, Hope SV, Bowman P, Oram RA, Knight BA, Hattersley AT (2011). Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes. Diabet Med, 28(9), 1034-1038. Abstract.  Author URL.

2010

Shields BM, Shepherd MH, McDonald T, Besser REJ, Jones AG, Raju NB, Wensley KJ, Githens-Mazer G, Knight BA, Hattersley AT, et al (2010). Clinical Criteria Are Poor at Identifying Type 1 Diabetes. Should We be Measuring Insulin Deficiency Directly?.  Author URL.
Jones AG, Hope SV, Shepherd M, Shields BM, Besser REJ, Wensley KJ, Githens-Mazer G, McDonald TJ, Knight BA, Hattersley AT, et al (2010). Do patients with Long-Standing Type 2 Diabetes Develop Absolute Insulin Deficiency?.  Author URL.
Jones AG, Hattersley AT (2010). Reevaluation of a case of type 1 diabetes mellitus diagnosed before 6 months of age. Nat Rev Endocrinol, 6(6), 347-351. Abstract.  Author URL.
Jones AG, Besser REJ, McDonald TJ, Wensley KJ, Githens-Mazer G, Shields BM, Knight BA, Hattersley AT (2010). Serum Measurement of Endogenous C-Peptide after a Mixed Meal can be Replaced with a Single Post Meal Urine C-Peptide Creatinine Ratio (UCPCR).  Author URL.
Shields BM, McDonald TJ, Bowman P, Jones AG, Besser REJ, Wensley KJ, Githens-Mazer G, Knight BA, Hattersley AT (2010). Urinary C-Peptide Creatinine Ratio (UCPCR) is a Reliable Measure of Endogenous Insulin Secretion, Even in Patients with Renal Impairment.  Author URL.
Besser REJ, Jones AG, McDonald TJ, Shields BM, Githens-Mazer G, Wensley K, Knight BA, Hattersley AT (2010). Urinary C-Peptide Creatinine Ratio is a Novel Non Invasive Alternative to the Inpatient Mixed Meal Tolerance Test in Young Onset Type 1 Diabetes.  Author URL.

2005

Edwards RJ, Taylor GW, Ferguson M, Murray S, Rendell N, Wrigley A, Bai Z, Boyle J, Finney SJ, Jones A, et al (2005). Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J Infect Dis, 192(5), 783-790. Abstract.  Author URL.

Back | Edit Profile